RU2015144020A - Среды для культивирования клеток и способы получения антител - Google Patents
Среды для культивирования клеток и способы получения антител Download PDFInfo
- Publication number
- RU2015144020A RU2015144020A RU2015144020A RU2015144020A RU2015144020A RU 2015144020 A RU2015144020 A RU 2015144020A RU 2015144020 A RU2015144020 A RU 2015144020A RU 2015144020 A RU2015144020 A RU 2015144020A RU 2015144020 A RU2015144020 A RU 2015144020A
- Authority
- RU
- Russia
- Prior art keywords
- cell culture
- culture medium
- concentration
- insulin
- hydrolyzate
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 274
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 266
- 239000006143 cell culture medium Substances 0.000 claims 218
- 102000004877 Insulin Human genes 0.000 claims 133
- 108090001061 Insulin Proteins 0.000 claims 133
- 229940125396 insulin Drugs 0.000 claims 133
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims 77
- 229960003067 cystine Drugs 0.000 claims 77
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 52
- 229940108928 copper Drugs 0.000 claims 52
- 229910052802 copper Inorganic materials 0.000 claims 52
- 239000010949 copper Substances 0.000 claims 52
- 238000004113 cell culture Methods 0.000 claims 49
- 241001465754 Metazoa Species 0.000 claims 46
- 239000002609 medium Substances 0.000 claims 42
- 210000004027 cell Anatomy 0.000 claims 37
- 229960000397 bevacizumab Drugs 0.000 claims 31
- 239000012634 fragment Substances 0.000 claims 31
- 238000012258 culturing Methods 0.000 claims 24
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 20
- 235000018417 cysteine Nutrition 0.000 claims 20
- 210000004962 mammalian cell Anatomy 0.000 claims 18
- 150000007523 nucleic acids Chemical class 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 239000012526 feed medium Substances 0.000 claims 1
- 230000001502 supplementing effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/33—Insulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361801247P | 2013-03-15 | 2013-03-15 | |
| US61/801,247 | 2013-03-15 | ||
| PCT/US2014/029758 WO2014145091A1 (en) | 2013-03-15 | 2014-03-14 | Cell culture media and methods of antibody production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015144020A true RU2015144020A (ru) | 2017-04-21 |
Family
ID=51537877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015144020A RU2015144020A (ru) | 2013-03-15 | 2014-03-14 | Среды для культивирования клеток и способы получения антител |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US9441035B2 (enExample) |
| EP (1) | EP2968544A4 (enExample) |
| JP (2) | JP2016513478A (enExample) |
| KR (1) | KR102202476B1 (enExample) |
| CN (1) | CN105246510A (enExample) |
| AR (1) | AR095348A1 (enExample) |
| BR (1) | BR112015022529A2 (enExample) |
| CA (1) | CA2903589A1 (enExample) |
| HK (1) | HK1213179A1 (enExample) |
| MX (1) | MX366112B (enExample) |
| RU (1) | RU2015144020A (enExample) |
| WO (1) | WO2014145091A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012001742A (es) | 2009-08-11 | 2012-03-21 | Genentech Inc | Produccion de proteinas en medios de cultivo de celulas libres de glutamina. |
| KR102007930B1 (ko) | 2014-12-31 | 2019-08-06 | 주식회사 엘지화학 | 재조합 당단백질의 글리코실화 조절 방법 |
| AR104050A1 (es) | 2015-03-26 | 2017-06-21 | Chugai Pharmaceutical Co Ltd | Proceso de producción con iones de cobre controlados |
| KR102595048B1 (ko) * | 2016-11-07 | 2023-10-26 | 씨젠 인크. | 조작된-시스테인 캡의 분포 |
| GB201708655D0 (en) | 2017-05-31 | 2017-07-12 | Ucb Biopharma Sprl | Cell culture methods |
| EP3727629A1 (en) | 2017-12-22 | 2020-10-28 | Regeneron Pharmaceuticals, Inc. | System and method for characterizing drug product impurities |
| CN108823267B (zh) * | 2018-06-25 | 2020-05-08 | 深圳市菲鹏生物制药股份有限公司 | 调节cho-k1表达系统所分泌抗体的酸性峰含量的方法 |
| US20240043486A1 (en) * | 2020-12-08 | 2024-02-08 | Partner Therapeutics, Inc. | Manufacture of granulocyte macrophage-colony stimulating factor |
| CN116635416A (zh) * | 2020-12-22 | 2023-08-22 | 诺华股份有限公司 | 用于在细胞培养期间降低分泌的重组表达蛋白质中半胱氨酸残基的氧化水平的方法 |
| WO2022233770A1 (en) * | 2021-05-03 | 2022-11-10 | Boehringer Ingelheim International Gmbh | Method for producing spesolimab |
| AU2023250258A1 (en) * | 2022-04-06 | 2024-11-14 | Kashiv Biosciences, Llc | An improved cell culture process for production of protein |
| EP4587552A1 (en) * | 2022-11-09 | 2025-07-23 | Infors AG | Incubator avoiding condensation |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| AU632065B2 (en) | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| ATE102631T1 (de) | 1988-11-11 | 1994-03-15 | Medical Res Council | Klonierung von immunglobulin sequenzen aus den variabelen domaenen. |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE69029036T2 (de) | 1989-06-29 | 1997-05-22 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| CA2050918A1 (en) | 1990-01-12 | 1991-07-13 | Raju Kucherlapati | Generation of xenogeneic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69133476T2 (de) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5122469A (en) * | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| EP0564531B1 (en) | 1990-12-03 | 1998-03-25 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| ATE419355T1 (de) | 1992-02-06 | 2009-01-15 | Novartis Vaccines & Diagnostic | Marker für krebs und biosynthetisches bindeprotein dafür |
| JPH08500017A (ja) | 1992-08-17 | 1996-01-09 | ジェネンテク，インコーポレイテッド | 二特異的免疫アドヘジン |
| WO1994011026A2 (en) | 1992-11-13 | 1994-05-26 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP0921855B1 (en) | 1996-08-30 | 2003-11-19 | Upfront Chromatography A/S | Isolation of immunoglobulins |
| DK1500329T3 (da) | 1996-12-03 | 2012-07-09 | Amgen Fremont Inc | Humane antistoffer, der specifikt binder TNF-alfa |
| US20080318254A9 (en) | 1997-03-10 | 2008-12-25 | The Regents Of The University Of California | PSCA antibodies and hybridomas producing them |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| US6884879B1 (en) * | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| ATE293640T1 (de) | 1997-04-07 | 2005-05-15 | Genentech Inc | Anti-vegf antikörper |
| US20020173629A1 (en) | 1997-05-05 | 2002-11-21 | Aya Jakobovits | Human monoclonal antibodies to epidermal growth factor receptor |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| US6528286B1 (en) * | 1998-05-29 | 2003-03-04 | Genentech, Inc. | Mammalian cell culture process for producing glycoproteins |
| DE60039596D1 (de) | 1999-03-30 | 2008-09-04 | Japan Tobacco Inc | Verfahren zur herstellung von monoklonalen antikörpern |
| DE60031999T2 (de) | 1999-10-04 | 2007-06-06 | Novartis Vaccines and Diagnostics, Inc., Emeryville | Stabilisierte flüssige polypeptid-haltige pharmazeutische zusammensetzungen |
| ES2248127T3 (es) | 1999-10-04 | 2006-03-16 | Medicago Inc. | Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno. |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| NZ526173A (en) * | 2000-11-06 | 2005-03-24 | Invitrogen Corp | Dry powder cells and cell culture reagents and methods of production thereof |
| CA2447114A1 (en) | 2001-05-16 | 2002-11-21 | Abgenix, Inc. | Human antipneumococcal antibodies from non-human animals |
| WO2003046162A2 (en) * | 2001-11-28 | 2003-06-05 | Polymun Scientific Immunbiologische Forschung Gmbh | Process for the production of polypeptides in mammalian cell cultures |
| CN1703233A (zh) | 2002-07-12 | 2005-11-30 | 米德列斯公司 | 防止蛋白氧化降解的方法和组合物 |
| CN1761482A (zh) | 2003-01-17 | 2006-04-19 | 纽约州立大学研究基金会 | 与胰腺癌相关的抗原、针对它的抗体以及诊断和治疗方法 |
| US7456264B2 (en) | 2003-05-21 | 2008-11-25 | Medarex, Inc. | Human monoclonal antibodies against Bacillus anthracis protective antigen |
| US20060115901A1 (en) * | 2004-10-22 | 2006-06-01 | Bahram Valamehr | Method and media for single cell serum-free culture of CHO cells |
| US8530192B2 (en) * | 2005-02-11 | 2013-09-10 | Novo Nordisk Healthcare Ag | Production of a polypeptide in a serum-free cell culture liquid containing plant protein hydrolysate |
| CN100362098C (zh) * | 2005-09-29 | 2008-01-16 | 华东理工大学 | 适用于多种动物细胞大规模培养的无血清培养基 |
| JP4976502B2 (ja) * | 2007-10-15 | 2012-07-18 | 中外製薬株式会社 | 抗体の製造方法 |
| EP2334323A2 (en) | 2008-09-10 | 2011-06-22 | F. Hoffmann-La Roche AG | Compositions and methods for the prevention of oxidative degradation of proteins |
| KR20110074564A (ko) * | 2008-09-24 | 2011-06-30 | 메디뮨 엘엘씨 | 세포 배양, 바이러스 증식 및 바이러스 정제를 위한 방법 |
| JP5749930B2 (ja) * | 2008-10-28 | 2015-07-15 | 中外製薬株式会社 | ペプチド含有動物細胞培養用培地 |
| CN101603026B (zh) * | 2009-06-19 | 2011-01-19 | 华东理工大学 | 适于动物细胞产品生产的无动物来源低蛋白培养基 |
| CN102471377B (zh) * | 2009-07-24 | 2015-04-22 | 霍夫曼-拉罗奇有限公司 | 优化抗体的生产 |
| MX2012001742A (es) * | 2009-08-11 | 2012-03-21 | Genentech Inc | Produccion de proteinas en medios de cultivo de celulas libres de glutamina. |
| WO2011091350A2 (en) * | 2010-01-25 | 2011-07-28 | Ventria Bioscience | Methods & compositions for improving protein production |
| US9133493B2 (en) * | 2011-04-21 | 2015-09-15 | Amgen Inc. | Method for culturing mammalian cells to improve recombinant protein production |
| US20130281355A1 (en) * | 2012-04-24 | 2013-10-24 | Genentech, Inc. | Cell culture compositions and methods for polypeptide production |
| US8956830B2 (en) * | 2013-03-14 | 2015-02-17 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
-
2014
- 2014-03-14 CA CA2903589A patent/CA2903589A1/en not_active Abandoned
- 2014-03-14 WO PCT/US2014/029758 patent/WO2014145091A1/en not_active Ceased
- 2014-03-14 RU RU2015144020A patent/RU2015144020A/ru not_active Application Discontinuation
- 2014-03-14 KR KR1020157029225A patent/KR102202476B1/ko active Active
- 2014-03-14 HK HK16101113.2A patent/HK1213179A1/zh unknown
- 2014-03-14 MX MX2015011781A patent/MX366112B/es active IP Right Grant
- 2014-03-14 CN CN201480027392.9A patent/CN105246510A/zh active Pending
- 2014-03-14 BR BR112015022529A patent/BR112015022529A2/pt not_active Application Discontinuation
- 2014-03-14 AR ARP140101052A patent/AR095348A1/es unknown
- 2014-03-14 EP EP14763258.2A patent/EP2968544A4/en not_active Withdrawn
- 2014-03-14 JP JP2016503216A patent/JP2016513478A/ja active Pending
- 2014-03-14 US US14/211,467 patent/US9441035B2/en active Active
-
2015
- 2015-09-11 US US14/852,382 patent/US20160102141A1/en not_active Abandoned
-
2016
- 2016-07-29 US US15/224,113 patent/US20170051049A1/en not_active Abandoned
-
2019
- 2019-06-18 JP JP2019112773A patent/JP2019193643A/ja active Pending
- 2019-10-18 US US16/657,844 patent/US20200291103A1/en not_active Abandoned
- 2019-11-15 US US16/685,798 patent/US20200347122A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX366112B (es) | 2019-06-26 |
| HK1213179A1 (zh) | 2016-06-30 |
| US9441035B2 (en) | 2016-09-13 |
| US20200347122A1 (en) | 2020-11-05 |
| KR102202476B1 (ko) | 2021-01-12 |
| US20160102141A1 (en) | 2016-04-14 |
| CA2903589A1 (en) | 2014-09-18 |
| MX2015011781A (es) | 2016-04-04 |
| EP2968544A4 (en) | 2016-10-12 |
| BR112015022529A2 (pt) | 2017-07-18 |
| US20200291103A1 (en) | 2020-09-17 |
| US20170051049A1 (en) | 2017-02-23 |
| CN105246510A (zh) | 2016-01-13 |
| JP2019193643A (ja) | 2019-11-07 |
| AR095348A1 (es) | 2015-10-07 |
| JP2016513478A (ja) | 2016-05-16 |
| US20140308273A1 (en) | 2014-10-16 |
| KR20150131258A (ko) | 2015-11-24 |
| WO2014145091A1 (en) | 2014-09-18 |
| EP2968544A1 (en) | 2016-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015144020A (ru) | Среды для культивирования клеток и способы получения антител | |
| AR132548A2 (es) | Medio de cultivo para células cho libre de suero que comprende ornitina y putrescina, método para cultivar células cho y método in vitro para producir una proteína | |
| BR112021025359A2 (pt) | Composições de proteína anti-vegf e métodos para a produção das mesmas | |
| RU2015144172A (ru) | Композиции клеточных культур с антиоксидантами и способы получения полипептидов | |
| EA201270469A1 (ru) | Способы культивирования клеток млекопитающих для получения белка | |
| AR069956A1 (es) | Procesos para cultivar celulas mamiferas secretoras de proteinas sanguineas heterologas | |
| BR112022017216A2 (pt) | Método para produzir células exterminadoras naturais a partir de células-tronco pluripotentes | |
| BR112012027430A2 (pt) | processo de cultivo de células aprimorado | |
| RU2008113220A (ru) | Способ получения белков с использованием соединений, препятствующих старению | |
| TN2011000202A1 (en) | Integrated process for the production of bio-oil from micro-organisms | |
| RU2008152449A (ru) | Получение гликопротеинов | |
| MY169935A (en) | "a method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof" | |
| MX345399B (es) | Metodo de cultivo de celulas animales. | |
| BRPI0914440A8 (pt) | Método para produção biogênica de etanol e cianobactéria geneticamente modificada | |
| JP2016513478A5 (enExample) | ||
| MX351974B (es) | Cultivo de celulas de mamifero. | |
| BRPI0706801B8 (pt) | método de purificação de cardiomiócitos ou cardiomiócitos programados derivado de células-tronco ou fetos | |
| RU2014147018A (ru) | Композиции клеточной культуры и способы получения полипептидов | |
| SI2904092T1 (en) | Ingredients and procedures for the production of glycoproteins | |
| EA201270440A1 (ru) | Растения с улучшенными характеристиками урожайности и способ их получения | |
| CN106029871A (zh) | 通过优化培养基调节重组蛋白的半乳糖基化的方法 | |
| EA201490945A1 (ru) | Набор, содержащий заменитель сыворотки и лабильные факторы | |
| BR112022002584A2 (pt) | Célula de levedura, método para produzir um ou mais oligossacarídeos, composição de fermentação, método para recuperar um ou mais oligossacarídeos, método para modificar geneticamente uma célula de levedura | |
| HRP20231139T1 (hr) | Proizvodnja heteromultimernih proteina upotrebom stanica sisavaca | |
| Michels et al. | Effect of cooling in the night on the productivity and biochemical composition of Tetraselmis suecica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20190326 |